| 1/5 | US=39 / Patologia Lefferts JA, Tsongalis GJ. Molecular assessment of human disease in the clinical laboratory. In: Coleman WB, Tsongalis GJ. Molecular pathology: the molecular basis of human disease. Amsterdam: Elsevier, 2009. p. 605-12. ISBN 978-0-12-374419-7. DOENCA HUMANA; AVALIACAO MOLECULAR; LABORATORIO CLINICO; DOENCA INFECCIOSA MOLECULAR; DIAGNOSTICO MOLECULAR; BCR-ABL |
| 2/5 | US=67 / Biol/Mol Denis GV. Imatinib mesylate (gleevec) and the emergence of chemotherapeutic drug-resistant mutations. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 545-57. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. QUIMIOTERAPICOS; MUTACOES; RESISTENCIA AOS MEDICAMENTOS; MESILATO DE IMATINIBE; GLEEVEC; STI-571; LEUCEMIA MIELOGENA CRONICA; TUMOR ESTROMAL GASTROINTESTINAL; BCR-ABL; C-KIT; FATOR DE CELULA-TRONCO; BIOLOGIA ESTRUTURAL |
| 3/5 | US=69 / Câncer Jabbour E, Cortes J, Kantarjian H. Targeted therapy in chronic myeloid leukemia. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 87-99. ISBN 978-1-60327-423-4. TERAPIA-ALVO NA LEUCEMIA MIELOIDE CRONICA; LEUCEMIA MIELOIDE CRONICA; INIBIDOR DA TIROSINA QUINASE; RESISTENCIA; BCR-ABL |
| 4/5 | US=70 / Biol/Mol Bunz F. Cancer genetics in the clinic. In: ___. Principles of cancer genetics. New York: Springer, 2008. p. 259-79. ISBN 978-1-4020-6783-9. GENETICA DO CANCER; CLINICA; INFORMACAO GENETICA; CARCINOGENOS; GENES; CELULAS GERMINATIVAS; ALTERACOES GENETICAS; BIOMARCADORES; TERAPIA ANTI-CANCER; BCR-ABL; IMATINIBE; GEFITINIBE; TRAIL |
| 5/5 | US=92 / Biol/Mol Deininger M. Established cancer therapies: tyrosine kinase inhibitors. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 477-508. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9. TERAPIA-ALVO; BCR-ABL; FLT3; EGFR; TYROSISE INIBITORS QUINASE; IMATINIB; GEFITINIB; ERLOTINIB; CANCER; LEUCEMIA |